Evaluation of the risk of foreign compounds depends upon understanding the enzymes involved their degradation. A set of under-studied metabolic enzymes include the epoxide hydrolases in the ?/?-hydrolase fold family. These enzymes degrade epoxides by adding water. Some epoxides are reactive and highly mutagenic, and epoxides are commonly formed as metabolically labile functionalities by cytochrome P450s from variety of environmental chemicals. Not only are the levels of epoxide hydrolases variable in the human population, but they can be inhibited or induced by environmental chemicals and drugs. A central hypothesis is that epoxide hydrolases also have endogenous roles. We have established that the soluble epoxide hydrolase also acts on epoxides of arachidonic acid. These are key regulatory lipids. In fact, an inhibitor of the soluble epoxide hydrolase we made during the last grant period is in clinical trials to treat hypertension. Because the soluble epoxide hydrolase is involved in the regulation of blood pressure, inflammation and pain, it additionally represents a novel target for the action of xenobiotics. Similarly, inhibition of the microsomal epoxide hydrolase leads to acute xenobiotic toxicity. The knowledge of ?/?-fold enzymes will be expanded by completing two major objectives, and the tools developed here are critical to test a series of hypotheses regarding the endogenous role of the soluble epoxide hydrolase. Objective I addresses the structure and fundamental biochemistry of epoxide hydrolases with a major emphasis on the less studied soluble form. Objective II continues the development of a metabolomic profiling system to examine biologically active lipids in the arachidonate cascade and related pathways. Using this analytical platform as well as potent inhibitors and inducers of the enzyme, the role of the soluble epoxide hydrolase as a key enzyme in the arachidonate cascade and thus regulation of inflammation and pain will be evaluated. Along with 15% of the world's pharmaceuticals, common herbicides and personal care products are also known to act on the arachidonate cascade. For example we have found the common soap anti microbial, triclocarban, is a potent inhibitor of the soluble epoxide hydrolase and the endogenous peptide angiotensin along with PPAR? agonists are inducers. By addressing our objectives, knowledge will be expanded on the biochemistry and role in xenobiotic metabolism of epoxide hydrolases. The hypothesis of endogenous roles for epoxide hydrolases will be tested and the arachidonate cascade evaluated as a site of action for xenobiotics and nutraceuticals.

Public Health Relevance

Epoxide hydrolase enzymes protect us against many environmental chemicals, and some of them also function to regulate our blood pressure, inflammation and pain. This study will identify new epoxide hydrolase targets for the action of drugs and nutraceuticals to improve health. This knowledge will also predict risk from environmental chemicals that increase or decrease the levels of epoxide hydrolases.

National Institute of Health (NIH)
National Institute of Environmental Health Sciences (NIEHS)
Research Project (R01)
Project #
Application #
Study Section
Xenobiotic and Nutrient Disposition and Action Study Section (XNDA)
Program Officer
Balshaw, David M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California Davis
Schools of Earth Sciences/Natur
United States
Zip Code
Burmistrov, Vladimir; Morisseau, Christophe; Pitushkin, Dmitry et al. (2018) Adamantyl thioureas as soluble epoxide hydrolase inhibitors. Bioorg Med Chem Lett 28:2302-2313
Tu, Ranran; Armstrong, Jillian; Lee, Kin Sing Stephen et al. (2018) Soluble epoxide hydrolase inhibition decreases reperfusion injury after focal cerebral ischemia. Sci Rep 8:5279
Taha, Ameer Y; Hennebelle, Marie; Yang, Jun et al. (2018) Regulation of rat plasma and cerebral cortex oxylipin concentrations with increasing levels of dietary linoleic acid. Prostaglandins Leukot Essent Fatty Acids 138:71-80
Kodani, Sean D; Wan, Debin; Wagner, Karen M et al. (2018) Design and Potency of Dual Soluble Epoxide Hydrolase/Fatty Acid Amide Hydrolase Inhibitors. ACS Omega 3:14076-14086
Ren, Qian; Ma, Min; Yang, Jun et al. (2018) Soluble epoxide hydrolase plays a key role in the pathogenesis of Parkinson's disease. Proc Natl Acad Sci U S A 115:E5815-E5823
Pecic, Stevan; Zeki, Amir A; Xu, Xiaoming et al. (2018) Novel piperidine-derived amide sEH inhibitors as mediators of lipid metabolism with improved stability. Prostaglandins Other Lipid Mediat 136:90-95
Yamanashi, Haruto; Boeglin, William E; Morisseau, Christophe et al. (2018) Catalytic activities of mammalian epoxide hydrolases with cis and trans fatty acid epoxides relevant to skin barrier function. J Lipid Res 59:684-695
Wang, Fuli; Zhang, Hongyong; Ma, Ai-Hong et al. (2018) COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin. Mol Cancer Ther 17:474-483
Napimoga, M H; Rocha, E P; Trindade-da-Silva, C A et al. (2018) Soluble epoxide hydrolase inhibitor promotes immunomodulation to inhibit bone resorption. J Periodontal Res 53:743-749
Blöcher, René; Wagner, Karen M; Gopireddy, Raghavender R et al. (2018) Orally Available Soluble Epoxide Hydrolase/Phosphodiesterase 4 Dual Inhibitor Treats Inflammatory Pain. J Med Chem 61:3541-3550

Showing the most recent 10 out of 450 publications